Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03294135
Other study ID # 205847
Secondary ID 2017-001356-59
Status Completed
Phase Phase 4
First received
Last updated
Start date October 5, 2017
Est. completion date October 25, 2021

Study information

Verified date September 2023
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine. This study will further investigate the booster response in subjects who will receive their second booster dose* in this study. * Any booster given in this study will be the second that the subject has received (with regard to the follow-up of the previous study).


Recruitment information / eligibility

Status Completed
Enrollment 194
Est. completion date October 25, 2021
Est. primary completion date October 25, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria: Inclusion criteria for all subjects: - Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. - Written informed consent obtained from the subject prior to performance of any study specific procedure. - Subjects who have participated in study V48P7E2 (NCT01562444) and who received in the parent V48P7 study one of the following schedules: rapid, conventional, or accelerated conventional and a booster vaccination in study V48P7E1 (NCT00387634) or before study V48P7E1 (NCT00387634) (only rapid schedule). Additional inclusion criteria for subjects who will need a second booster dose: - Healthy subjects as established by medical history and clinical examination before entering into the study. - Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. - Female subjects of childbearing potential can receive the booster vaccine in the study, if the subject: has practiced adequate contraception for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception for 2 months after booster administration. Exclusion Criteria: Each subject must not be: - Unwilling or unable to give written informed consent to participate in the study. - Perceived to be unreliable or unavailable to complete the study. Each subject must not have: - Clinical conditions representing a contraindication to blood draws. - Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study. - Received an investigational or non-registered medicinal product within 30 days prior to informed consent. - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. - Levels of NT<10 in V48P7E2 (NCT01562444) study. - Previous vaccination against TBE or other Flavivirus diseases with other TBE and Flavivirus vaccines (e.g. Yellow fever vaccine, Dengue fever vaccine, Japanese encephalitis vaccine) before, during and after completion of the V48P7E2 (NCT01562444) and before starting TBEV POLYGELINE FREE-025 EXT 21 study. - Primary immunization with TBE vaccine in the parent study V48P7 according to the modified conventional (MC) schedule. - History of confirmed TBE infection. - Known exposure to other Flaviviruses. Each subject who will receive the second booster vaccination in this study additionally to the exclusion criteria above must not have: - Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study. - Clinical conditions representing a contraindication to intramuscular vaccination. - Progressive, unstable or uncontrolled clinical conditions. - Abnormal function of the immune system resulting from: Clinical conditions. Systemic administration of corticosteroids for more than 14 consecutive days within 90 days prior to informed consent. This will mean prednisone =20 mg/day (for adult subjects) or equivalent. Inhaled and topical steroids are allowed. Administration of antineoplastic and immuno-modulating agents or radiotherapy within 90 days prior to vaccination. - Received immunoglobulins or any blood products within 180 days prior to vaccination. - Administration of long-acting immune-modifying drugs at any time during the study period. - Acute disease and/or fever at the day of booster vaccination. - Expected general decrease in immune response. - Organic brain disturbances, including seizure disorders. - Progressive neurological disorders. - Suffered febrile or afebrile convulsions. - Serious chronic illness. - History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or chemically related substances. - Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to vaccination in this study or who are planning to receive any vaccine within 28 days from the study vaccines. - Pregnant.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Encepur Adults
One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.

Locations

Country Name City State
Czechia GSK Investigational Site Hradec Kralove

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Czechia, 

References & Publications (1)

Beran J, Lattanzi M, Costantini M, Pammolli A, Galgani I. Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up. Vaccine. 2023 May 26;41(23):3518-3524. doi: 10.1016/j.vaccine.2023.04.061. Epub 2023 May 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 11 Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers >= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period. At Year 11
Primary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 12 Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers >= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period. At Year 12
Primary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 13 Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers >= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period. At Year 13
Primary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 14 Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers >= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period. At Year 14
Primary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 10 at Year 15 Antibody titers were measured by GSK Biologicals' Neutralization test. Analysis of the percentages of participants with antibody titers >= 2 was not performed as planned in the protocol, as only 3 participants had antibody titers between 2 and 10 during the whole study period. At Year 15
Primary Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 11 Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 11. GMTs were assessed for following age subgroups: 25 to 49 years, equal to or above (>=) 50 years and >= 60 years. At Year 11
Primary Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 12 Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 12. GMTs were assessed for following age subgroups: 25 to 49 years, >= 50 years and >= 60 years. At Year 12
Primary Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 13 Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 13. GMTs were assessed for following age subgroups: 25 to 49 years, >= 50 years and >= 60 years. At Year 13
Primary Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 14 Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 14. GMTs were assessed for following age subgroups: 25 to 49 years, >= 50 years and >= 60 years. At Year 14
Primary Geometric Mean Antibody Titers (GMTs) by Age Categories at Year 15 Immunogenicity was measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at Year 15. GMTs were assessed for following age subgroups: 25 to 49 years, >= 50 years and >= 60 years. At Year 15
Secondary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to or Above 2 and Equal to or Above 10 as Measured by GSK Biologicals' NT, Overall and by Study Group Immunogenicity was planned to be measured in terms of percentage of participants with TBE Neutralizing Antibody Titers >= 2 and >= 10 at 21 days after the booster vaccination. At 21 days after the booster vaccination
Secondary Geometric Mean Antibody Titers (GMTs) as Measured by GSK Biologicals' NT, Overall and by Study Group Immunogenicity was planned to be measured in terms of GMTs of serum TBE Neutralizing Antibody Titers at 21 days after the booster vaccination. At 21 days after the booster vaccination
Secondary Geometric Mean Ratios (GMRs) Blood Draw After/Before Booster as Measured by GSK Biologicals' NT, Overall and by Study Group Immunogenicity was planned to be measured in terms of GMRs of serum TBE Neutralizing Antibody Titers at 21 days after the booster vaccination. At 21 days after the booster vaccination
Secondary Percentage of Participants With Detectable TBE Neutralizing Antibody Titers Equal to and Above 10 as Measured by GSK Biologicals' NT, Overall and by Study Group Immunogenicity was measured in terms of percentage of participants with TBE Neutralizing Antibody Titers >= 10 from Year 1 to Year 15. From Year 1 up to Year 15
Secondary Number of Participants With Serious Adverse Events (SAEs) SAEs are defined as any untoward medical occurrence that results in death, is life- threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. From Day 0 to Day 21 after booster vaccination
See also
  Status Clinical Trial Phase
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT04644484 - A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety Phase 3
Completed NCT00984945 - Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults Phase 1
Completed NCT00734175 - Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine Phase 1
Completed NCT00516035 - Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults Phase 1
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Completed NCT03739112 - Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Phase 3
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT01991587 - Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults Phase 1/Phase 2
Active, not recruiting NCT02545517 - A Clinical Study to Evaluate Immune Responses to Rabies Vaccine in Adults Who Received Different Primary Rabies Vaccination Regimens Phase 3
Active, not recruiting NCT05619770 - Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects Phase 1
Not yet recruiting NCT01289301 - Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant Phase 4
Active, not recruiting NCT01055990 - Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients Phase 2
Completed NCT01842997 - Safety of H1N1 Influenza Vaccination in Pregnant Women Phase 4
Completed NCT00980447 - Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults Phase 2
Completed NCT00380237 - Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) Phase 1
Completed NCT00219453 - Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination Phase 1
Completed NCT02548078 - A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Phase 2
Completed NCT01480258 - Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) Phase 3